Pathophysiology of Immune Reconstitution Inflammatory Syndrome (IRIS)
IRIS results from a dysregulated inflammatory response when recovering CD4+ T cells encounter high pathogen or antigen burden in patients initiating antiretroviral therapy at low CD4 counts, leading to excessive activation of both innate and adaptive immune systems that paradoxically worsens clinical status despite effective viral suppression. 1
Two Distinct Pathophysiologic Mechanisms
IRIS manifests through two phenomena that share common underlying mechanisms 1:
1. Unmasking IRIS
- Previously subclinical opportunistic infections become clinically apparent after ART initiation
- Common pathogens: disseminated MAC, tuberculosis, CMV retinitis, Pneumocystis pneumonia, Kaposi sarcoma 1
- The recovering immune system "unmasks" infections that were present but not generating sufficient inflammation to cause symptoms
2. Paradoxical IRIS
- Clinical worsening of a known, treated opportunistic infection after ART initiation 1
- Occurs despite appropriate pathogen-specific therapy
- Represents exaggerated inflammatory response to residual antigens
Core Pathophysiologic Mechanisms
The Innate-Adaptive Immune Dysregulation
The fundamental problem is hyper-responsiveness of the innate immune system to reconstituting T cell help, rather than simple T cell recovery alone 2. This involves:
- Pre-ART priming: High pathogen burden excessively primes innate immune cells (macrophages, dendritic cells) before T cell reconstitution 3
- Failure of pathogen clearance: Defective phagocyte function allows persistent high antigenic load, which becomes the substrate for inflammation 4
- Lymphopenia-induced proliferation: Rapid T cell expansion in a systemically activated, antigen-rich environment 4
CD4+ T Cell Dysfunction
The reconstituting T cell response is qualitatively abnormal 4, 5:
- Th1/Th17 bias: Exaggerated pro-inflammatory T cell responses, particularly prominent in TB-IRIS 5, 6
- Th2 skewing pre-ART: Many patients exhibit Th2-dominant, low-inflammatory states before ART that shift dramatically 6
- Regulatory T cell failure: Defective Treg function fails to control the inflammatory response 4
- Non-pathogen-specific activation: Self-antigen-specific T cells can also drive IRIS, not just pathogen-specific cells 3
IL-7 and Immune Reconstitution
- Increased IL-7 availability during lymphopenia drives rapid T cell expansion 4, 6
- This expansion occurs in the context of high antigen burden and systemic immune activation
- Creates conditions for disproportionate inflammatory responses
Chemokine-Mediated Trafficking
- CXCR3+ and CCR5+ effector T cells traffic to sites of antigen deposition 6
- Elevated chemokines (IP-10, interferon-γ) guide inflammatory cells to tissues 5
- Results in localized, tissue-destructive inflammation
Clinical Implications of Pathophysiology
IRIS causes considerable morbidity and occasional mortality 1, particularly with:
Critical Risk Factors Derived from Pathophysiology
- Low baseline CD4 count (<50 cells/μL): Greater degree of immune dysregulation 7
- High pathogen burden: More antigen to drive inflammation 4, 7
- Rapid viral suppression: Faster immune reconstitution 7
- Early ART initiation after OI diagnosis: Less time for pathogen clearance before immune recovery 7
Biomarkers Reflecting Pathophysiology
Elevated inflammatory markers predict or diagnose IRIS 5:
- C-reactive protein
- Interferon-inducible protein 10 (IP-10)
- Interferon-γ
- Pro-inflammatory cytokines and chemokines
These markers are elevated even before ART in unmasking IRIS cases, indicating pre-existing immune priming 5.
Beyond HIV: IRIS in Other Immunocompromised States
The same pathophysiologic principles apply to non-HIV IRIS 8, 9:
- Post-chemotherapy neutrophil recovery
- Post-transplant immunosuppression withdrawal
- Rapid corticosteroid taper
This confirms that the core mechanism is immune reconstitution encountering high antigen burden, regardless of the cause of initial immunosuppression 8.
Key Clinical Pitfall
The paradox of IRIS is that appropriate treatment (ART, pathogen-specific therapy) triggers clinical deterioration 1, 2. Clinicians must distinguish IRIS from treatment failure, new infections, or drug toxicity—a diagnostic challenge that requires understanding the underlying inflammatory pathophysiology rather than assuming therapeutic failure.